Previous 10 | Next 10 |
2023-08-30 08:17:19 ET Top KingWin ( TCJH ) +36% . Digital Brands Group ( DBGI ) +32% . Globalstar ( GSAT ) +12% . Dermata Therapeutics ( DRMA ) +13% . LexinFintech ( LX ) +8% Q2 earnings call release BioLineRx ...
2023-08-11 16:26:51 ET More on Dermata Therapeutics Dermata Therapeutics announces $1.8M offering priced ATM Dermata climbs ~28% after update on acne candidate Dermata Therapeutics launches $5M securities offering Dermata climbs after positive early stag...
- Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 - - Received positive feedback on its End of Phase 2 meeting package from FDA in June 2023 - - Phase 3 STAR-1 study is projected to start enrolling patients in the 2H 2023 - SAN DIEGO, C...
- FDA established key elements of the DMT310 Phase 3 clinical program and delineated a potential regulatory pathway for approval of DMT310 - -The DMT310 Phase 3 program will consist of two pivotal trials, STAR-1 and STAR-2 ( Spongilla Treatment of Acne Research Study )- - The first ...
SAN DIEGO, CA / ACCESSWIRE / June 13, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, announced today that Dermata's CEO, Gerald Proehl, has been invi...
- DMT310 once-weekly topical treatment demonstrated statistically significant improvements at all time points in the three primary endpoints, inflammatory lesion count, noninflammatory lesion count, and Investigator Global Assessment (IGA) - - DMT310 significantly reduced inflammatory lesion...
2023-06-02 08:33:10 ET U Power ( UCAR ) +70% . Connect Biopharma Holdings ( CNTB ) +53% Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis. ...
SAN DIEGO, CA / ACCESSWIRE / May 26, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced the closing of its previously announc...
2023-05-24 08:17:38 ET Dermata Therapeutics ( NASDAQ: DRMA ) has entered into a definitive agreement for the purchase and sale of an aggregate of ~0.8M shares of its common stock, at a purchase price of $2.285/share, in a registered direct offering priced ATM under Nasdaq rule...
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules SAN DIEGO, CA / ACCESSWIRE / May 24, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical ...
News, Short Squeeze, Breakout and More Instantly...
Dermata Therapeutics Inc. Company Name:
DRMA Stock Symbol:
NASDAQ Market:
Dermata Therapeutics Inc. Website:
SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreement...
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis - SAN...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...